Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MATK | P42679 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5400263 | 0.94 | GSK3B (0.50) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5388606 | 0.87 | GSK3B (0.54) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5388940 | 0.85 | MAPK14 (0.53) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5395995 | 0.85 | GSK3B (0.59) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5761865 | 0.84 | MAPK9 (0.62) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5395855 | 0.83 | MKNK1 (0.51) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5388349 | 0.83 | MAPK14 (0.55) | GSK3BMAPK14MAPK10 | |
| SCHEMBL5379424 | 0.83 | MAPK14 (0.54) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5398657 | 0.81 | MAPK9 (0.56) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5379033 | 0.81 | MAPK14 (0.58) | GSK3BMAPK14EGFRRAF1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | GSK3B 3047/4885MAPK14 1551/4885EGFR 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.